Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors
Metrics: PDF 902 views | HTML 2960 views | ?
María Laura Gutiérrez1, Luis Antonio Corchete2, María Eugenia Sarasquete2, María del Mar Abad3, Oscar Bengoechea3, Encarna Fermiñán4, María Fernanda Anduaga5, Sofía del Carmen3, Manuel Iglesias5, Carmen Esteban5, María Angoso5, Jose Antonio Alcazar5, Jacinto García5,*, Alberto Orfao1,*, Luis Muñoz-Bellvís5,* and José María Sayagués1,*
1Cytometry Service-NUCLEUS, Cancer Research Center, IBMCC-CSIC/USAL, Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca, Biomedical Research Networking Centre Consortium-CIBER-CIBERONC, Salamanca, Spain
2Cancer Research Center and Service of Hematology, University Hospital of Salamanca, Salamanca, Spain
3Department of Pathology, University Hospital of Salamanca, Salamanca, Spain
4Genomics Unit, Cancer Research Center, IBMCC-CSIC/USAL, Salamanca, Spain
5Service of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain
*These authors contributed equally to this work
Alberto Orfao, email: email@example.com
Keywords: sporadic colorectal cancer; metastatic; non-metastatic; primary tumor; gene expression profile
Received: August 30, 2017 Accepted: October 28, 2017 Published: November 21, 2017
Despite significant advances have been achieved in the genetic characterization of sporadic colorectal cancer (sCRC), the precise genetic events leading to the development of distant metastasis remain poorly understood. Thus, accurate prediction of metastatic disease in newly-diagnosed sCRC patients remains a challenge. Here, we evaluated the specific genes and molecular pathways associated with the invasive potential of colorectal tumor cells, through the assessment of the gene expression profile (GEP) of coding and non-coding genes in metastatic (MTX) vs. non-metastatic (non-MTX) primary sCRC tumors followed for >5 years. Overall, MTX tumors showed up-regulation of genes associated with tumor progression and metastatic potential while non-MTX cases displayed GEP associated with higher cell proliferation, activation of DNA repair and anti-tumoral immune/inflammatory responses. Based on only 19 genes a specific GEP that classifies sCRC tumors into two MTX-like and non-MTX-like molecular subgroups was defined which shows an independent prognostic impact on patient overall survival, particularly when it is combined with the lymph node status at diagnosis. In summary, we show an association between the global GEP of primary sCRC cells and their metastatic potential and defined a GEP-based classifier that provides the basis for further prognostic stratification of sCRC patients who are at risk of distant metastases.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.